| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 422.4 | 353.1 | 346.5 |
| Other income | 3.1 | 4.1 | 2.0 |
| Total income | 425.6 | 357.2 | 348.6 |
| Profit before exceptional items & tax | 80.3 | 54.5 | 60.9 |
| Profit before tax | 80.4 | 54.7 | 60.7 |
| Net profit | 60.1 | 45.3 | 46.2 |
| Operating margin | 18.9% | 15.3% | 17.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +30.10% |
|---|---|
| Net profit, quarter on quarter | +32.70% |
| Revenue, year on year | +21.90% |
| Operating profit, year on year | +29.00% |
| Operating profit, quarter on quarter | +38.30% |
BSE results filing, NSE: CORONA. Figures extracted from the filing.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,117.70
- Market cap
- ₹12,952 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 65.1×Sector 50.4×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 3.63%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Capital Structure Change
Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,629,880 equity shares of Corona Remedies Limited. This non-promoter stake sale is disclosed under SEBI SAST regulations.
Corona Remedies Price Movement Clarification
CORONA Remedies Limited clarified that the recent increase in its share trading volume is purely market-driven and no undisclosed price-sensitive information exists.
Corona Remedies Earnings Call Transcript: Key Takeaways
Corona Remedies reported robust Q1 FY27 results with 21.9% revenue growth and 33.5% EBITDA growth. Strategy focuses on chronic therapies and scaling brand portfolios.
- Call
- Guides 20% growth
Corona Remedies Investor Presentation: Key Takeaways
Corona Remedies reported strong Q1FY27 performance with 21.9% revenue growth and 33.5% EBITDA growth, driven by its strategic shift towards chronic therapies which now contribute ~73.4% of revenue.
Corona Remedies Earnings Call: Key Takeaways
Corona Remedies reported strong FY26 results, outperforming industry growth via specialty chronic segments and strategic acquisitions like Wokadine and the Bayer portfolio.
Corona Remedies Earnings Call: Key Takeaways
CORONA Remedies reported 17.3% FY26 revenue growth to ₹1,403.2 Cr, driven by chronic therapy focus and strategic acquisitions like Wokadine. Company maintain's 20.9% EBITDA margins.